Livedoid vasculopathy: Case report and brief review of its therapy
International Journal of Development Research
Livedoid vasculopathy: Case report and brief review of its therapy
Received 17th April, 2022; Received in revised form 27th May, 2022; Accepted 03rd June, 2022; Published online 28th July, 2022
Copyright © 2022, Frederico Lima de Siqueira Dantas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
A 58-year-old man, with purpuric pericapillary lesions in the lower limbs, for 20 years, associated with local hyperesthesia. The condition evolved with local burning extending to the back of the feet. Pentoxifylline, acetylsalicylic, diosmine, syvastatin and cilostazol were used. In the current consultation, he had erythema-vinous macules in the distal part of the thighs and on both legs ranging from a few mm to 2 cm in diameter associated with continuity solutions and white atrophies. With a suspicion of Livedoid Vasculopathy, laboratory tests were performed: liver and kidney function tests, glucose, alkaline phosphatase, blood count, serum complement, ANF (antinuclear factor), urine summary, anti-RNP, native anti-DNA, anti-SLC-70, anti-U1 RNP, anti-ACA, dehydrogenases, fibrinogen, serology for syphilis, hepatitis B and C and HIV, all exams were normal, The CH50 was at 80 U/ml (normal up to 60 U/ml). The histopathological study of cutaneous fragment confirming the initial suspicion. Therapy for livedoid vasculopathy includes intravenous pulse immunoglobulin which has been shown to be effective and safe, providing responses, in some cases, from the first cycle (Kim et al 2015), and danazol, with high fibrinolytic power.